Drug intelligence / Profile preview

PAT205 + PAT206

Development stage: Preclinical
Lead developer: ProAbTech
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

PAT205 and PAT206 are long-acting recombinant uricase (urate oxidase) enzymes developed by ProAbTech for the treatment of chronic gout and hyperuricemia. These candidates utilize ProAbTech's proprietary Albubody™ and SelecAll™ bioconjugation platforms, which facilitate the site-specific attachment of albumin to the enzyme. This modification is intended to extend the therapeutic half-life and minimize the immunogenic response typically associated with non-human uricase treatments. ProAbTech has partnered with BNC Korea and KH NeoChem for the development of these assets, which aim to provide a more durable reduction in serum uric acid levels compared to existing therapies.

Other names: PAT205 + PAT206-ProAbTech

Beyond the preview

Go deeper on PAT205 + PAT206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAT205 + PAT206.

Explore the full profile